Synthesis and Anticancer Properties of Oxazepines Related to Azaisoerianin and IsoCoQuines.
Antineoplastic Agents
/ chemical synthesis
Aza Compounds
/ chemistry
Cell Cycle
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Dose-Response Relationship, Drug
Drug Screening Assays, Antitumor
Humans
Models, Molecular
Molecular Structure
Oxazepines
/ chemical synthesis
Structure-Activity Relationship
Tubulin
/ metabolism
Tubulin Modulators
/ chemical synthesis
Tumor Cells, Cultured
cancer
cytotoxicity
isoCA-4
oxazepine
quinoline
Journal
ChemMedChem
ISSN: 1860-7187
Titre abrégé: ChemMedChem
Pays: Germany
ID NLM: 101259013
Informations de publication
Date de publication:
19 08 2020
19 08 2020
Historique:
received:
30
03
2020
pubmed:
3
6
2020
medline:
16
6
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
In this article, we report the synthesis and biological properties of a series of novel oxazepines related to isoCA-4 having significant antitumor properties. Among them, three oxazepin-9-ol derivatives display a nanomolar or a sub-nanomolar cytotoxicity level against five human cancer cell lines (HCT116, U87, A549, MCF7, and K562). It was demonstrated that the lead compound in this series inhibits tubulin assembly with an IC
Identifiants
pubmed: 32485077
doi: 10.1002/cmdc.202000197
doi:
Substances chimiques
Antineoplastic Agents
0
Aza Compounds
0
Oxazepines
0
Tubulin
0
Tubulin Modulators
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1571-1578Informations de copyright
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
G. R. Pettit, S. B. Singh, E. Hamel, C. M. Lin, D. S. Alberts, D. Garcia-Kendall, Experientia 1989, 45, 209-211.
C. M. Lin, H. H. Ho, G. R. Pettit, E. Hamel, Biochemistry 1989, 28, 6984-6991.
A. T. Mc Gown, B. W. Fox, Cancer Chemother. Pharmacol. 1990, 26, 79-81.
G. M. Tozer, V. E. Prise, J. Wilson, R. J. Locke, B. Vojnovic, M. R. Stratford, M. F. Dennis, D. J. Chaplin, Cancer Res. 1999, 59, 1626-1634.
G. M. Tozer, C. Kanthou, C. S. Parkins, S. A. Hill, Int. J. Exp. Pathol. 2002, 83, 21-38.
G. G. Dark, S. A. Hill, V. E. Prise, G. M. Tozer, G. R. Pettit, D. J. Chaplin, Cancer Res. 1997, 57, 1829-1834.
www.mateon.com.
K. Ohsumi, T. Hatanaka, R. Fujita, R. Nakagawa, Y. Fukuda, Y. Nihei, Y. Suga, Y. Morinaga, Y. Akiyama, T. Tsuji, Bioorg. Med. Chem. Lett. 1998, 8, 3153-3158.
S. Aprile, E. Del Grosso, G. C. Tron, G. Grosa, Drug Metab. Dispos. 2007, 35, 2252-2261.
O. Provot, A. Hamze, J. F. Peyrat, J. D. Brion, M. Alami, Anticancer Agents Med. Chem. 2013, 13, 1614-1635.
S. Messaoudi, B. Tréguier, A. Hamze, O. Provot, J. F. Peyrat, J. R. Rodrigo De Losada, J. M. Liu, J. Bignon, J. Wdzieczak-Bakala, S. Thoret, J. Dubois, J. D. Brion, M. Alami, J. Med. Chem. 2009, 52, 4538-4542.
A. Hamze, A. Giraud, S. Messaoudi, O. Provot, J. F. Peyrat, J. Bignon, J. M. Liu, J. Wdzieczak-Bakala, S. Thoret, J. Dubois, J. D. Brion, M. Alami, ChemMedChem 2009, 4, 1912-1924.
S. Messaoudi, A. Hamze, O. Provot, B. Tréguier, J. Rodrigo De Losada, J. Bignon, J.-M. Liu, J. Wdzieczak-Bakala, S. Thoret, J. Dubois, J.-D. Brion, M. Alami, ChemMedChem 2011, 6, 488-497.
M. A. Soussi, O. Provot, G. Bernadat, J. Bignon, J. Wdzieczak-Bakala, D. Desravines, J. Dubois, J. D. Brion, S. Messaoudi, M. Alami, Eur. J. Med. Chem. 2014, 78, 178-189.
A. Hamze, E. Rasolofonjatovo, O. Provot, C. Mousset, D. Veau, J. Rodrigo, J. Bignon, J. M. Liu, J. Wdzieczak-Bakala, S. Thoret, J. Dubois, J. D. Brion, M. Alami, ChemMedChem 2011, 6, 2179-2191.
E. Rasolofonjatovo, O. Provot, A. Hamze, J. Rodrigo, J. Bignon, J. Wdzieczak-Bakala, D. Desravines, J. Dubois, J. D. Brion, M. Alami, Eur. J. Med. Chem. 2012, 52, 22-32.
D. Renko, E. Rasolofonjatovo, O. Provot, J. Bignon, J. Rodrigo, J. Dubois, J. D. Brion, A. Hamze, M. Alami, Eur. J. Med. Chem. 2015, 90, 834-844.
E. Rasolofonjatovo, O. Provot, A. Hamze, J. Rodrigo, J. Bignon, J. Wdzieczak-Bakala, C. Lenoir, D. Desravines, J. Dubois, J. D. Brion, M. Alami, Eur. J. Med. Chem. 2013, 62, 28-39.
] M. A. Soussi, O. Provot, G. Bernadat, J. Bignon, D. Desravines, J. Dubois, J. D. Brion, S. Messaoudi, M. Alami, ChemMedChem 2015, 10, 1392-1402.
I. Khelifi, T. Naret, D. Renko, A. Hamze, G. Bernadat, J. Bignon, C. Lenoir, J. Dubois, J. D. Brion, O. Provot, M. Alami, Eur. J. Med. Chem. 2017, 127, 1025-1034.
T. Naret, I. Khelifi, O. Provot, J. Bignon, H. Levaique, J. Dubois, M. Souce, A. Kasselouri, A. Deroussent, A. Paci, P. Varela, B. Gigant, M. Alami, A. Hamze, J. Med. Chem. 2019, 62, 1902-1916.
I. Khelifi, T. Naret, T. A. Hamze, J. Bignon, H. Levaique, C. Garcia, J. Dubois, O. Provot, M. Alami, Eur. J. Med. Chem., 2019, 168, 176-188.
Y. Zhou, W. Yan, D. Cao, M. Shao, D. Li, F. Wang, Z. Yang, Y. Chen, L. He, T. Wang, M. Shen, L. Chen , Eur. J. Med. Chem. 2017, 138, 1114-1125.
X.-F. Wang, F. Guan, E. Ohkoshi, W. Guo, L. Wang, D.-Q. Zhu, S.-B. Wang, L.-T. Wang, E. Hamel, D. Yang, L. Li, K. Qian, S. L. Morris-Natschke, S. Yuan, K.-H. Lee, L. Xie, J. Med. Chem. 2014, 57, 1390-1402.
X.-F. Wang, S.-B. Wang, E. Ohkoshi, L.-T. Wang, E. Hamel, K. Qian, S. L. Morris-Natschke, K.-H. Lee, L. Xie, Eur. J. Med. Chem. 2013, 67, 196-207.
S. Kasibhatla, V. Baichwal, S. X. Cai, B. Roth, I. Skvortsova, S. Skvortsov, P. Lukas, N. M. English, N. Sirisoma, J. Drewe, A. Pervin, B. Tseng, R. O. Carlson, C. M. Pleiman, Cancer Res. 2007, 67, 5865-5871.
Y. Ana, E. Leea, Y. Yu, J. Yun, M. Y. Lee, J. S. Kang, W.-Y. Kim, R. Jeon, Bioorg. Med. Chem. Lett. 2016, 26, 3076-3072.
Amine 6 was found to be unstable on SiO2 gel column and was used without purification for the next cyclization step.
Q. Sun, W. Zhang, H. Yuan, F. Z. Shenqing, CN 104860908 A 20150826, 2015..
A. Giraud, O. Provot, A. Hamze, J. D. Brion, M. Alami, Tetrahedron Lett. 2008, 49, 1107-1110.
In the majority of cases concerning isoCA-4 analogues, a OH group leads to the more cytotoxic compounds even if other small groups are permitted with slightly inferior cytotoxicities. For a review concerning SARs on isoCA-4, see: M. Alami, A. Hamze, O. Provot, Eur. J. Med. Chem. 2020, 190, 112110.
The basis for this difference has been attributed to intracellular retention of these compounds, leading to higher intracellular concentrations, see: M. A. Jordan, K. Wendell, S. Gardiner, W. Brent Derry, H. Copp, L. Wilson, Death Cancer Res. 1996, 56, 816-825. Moreover, the tubulin polymerization test consists in a rapid turbidimetric assay that examines instantaneous effects on polymerization. The difference between long-term continuous treatment in the cell-based assay (72 h and instant measurements explain such concentration differences, see: G. C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, A. A. Genazzani, J. Med. Chem., 2006, 49, 3033-3044.
Analysis of the effects of 1 g on the cell cycle regulation can explain in part, the mode of action of this compound on cancer cells. It is reasonable to think that this mode of action will be the same on the five tested cell lines and that is not necessary to choose the most sensitive cell line (U87) as we used concentrations close to the IC50 values to achieve these cell cycle experiments. IsoCA4 was used as a positive control and the results obtained are identical to those previously published.
M. L. Shelanski, F. Gaskin, C. R. Cantor, Proc. Natl. Acad. Sci. USA 1973, 70, 765-768.
D. M. Barron, S. K. Chatterjee, R. Ravindra, R. Roof, E. Baloglu, D. G. I. Kingston, S. Bane, Anal. Biochem. 2003, 315, 49-56.
C. Venot, M. Maratrat, C. Dureuil, E. Conseiller, L. Bracco, L. Debussche, EMBO J. 1998, 17, 4668-4679.
E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin, J. Comput. Chem. 2004, 25, 1605-1612.
http://www.chemaxon.com.
O. Trott, A. J. Olson, J. Comput. Chem. 2010, 31, 455-461.